Merck and Co., Inc. v. Hi-Tech Pharmacal Co., Inc.
A term of a patent subject to a terminal disclaimer may be extended, pursuant to 35 U.S.C. § 156, to compensate for delays that occur during regulatory review.
Results for FDA review
view Case Detail
Download PDF